JA PCM

Personalised cancer medicine (PCM) using personal medical history, physiological status, genomic profiling combined with technologies like imaging are key in cancer management, from prevention to end-of-life care, and in some cases already a standard practice. The key aim of this Joint Action (JA) is to extend access to and knowledge of PCM across Europe with the vision to develop healthcare interventions along the individual’s lifecourse taking a multi-perspective point of view from the healthy person, cancer patient and survivor. The JA partners recognize that prevention, diagnosis, treatment, and follow-up should be approached in a concerted way for optimal patient benefit. The JA will thus focus on three areas: 1) personalised prevention and early detection, 2) personalised ‘medicine’, and 3) personalised follow-up and tertiary prevention. Pilot projects will build on previous initiatives like CAN.HEAL and PCM4EU, addressing seven key themes: 1) pathway, access and implementation of risk-informed cancer prevention, 2) polygenic risk score application, 3) cancer genetic predisposition across the patient journey, 4) molecular tumour boards, 5) innovative shared risk treatment models with evidence generation, 6) liquid biopsy testing, 7) digital innovation for remote monitoring. Transversal activities, such as EQA (External Quality Assessments) for liquid biopsy, education and training, ELSI (Ethical, Legal and Social Implications), HTA (Health Technology Assessment), data and access, will support these efforts. The outcomes will be evaluated using the 'Intervention Readiness Assessment tool' from CAN.HEAL. The JA will conclude with the ‘PCM in Europe’ roadmap and sustainability plan, aligning with other initiatives in the European Beating Cancer Plan (EBCP) that is entering the last phase.

Project number: ID No. 101233450, UL registration No. ZD2025/21959
Period: 01.11.2025. – 31.10.2029.
Project total funding: 25 280 904,88 EUR
UL total funding: 35 588,20 EUR

Partners: 149 organizations from 29 countries, including leading universities and national research institutes, clinical university hospitals, national cancer centers, healthcare institutions, and specialized public health organizations.

Coordinator: SCIENSANO (Belgium)
Partners: KLINICKI CENTAR UNIVERZITETA U SARAJEVU (Bosnia and Herzegovina), SVEUCILISNA KLINICKA BOLNICA MOSTAR (Bosnia and Herzegovina), KLINICKI BOLNICKI CENTAR SESTRE MILOSRDNICE (Croatia), ORGANISMOS ASFALISIS YGEIAS (Cyprus), USTAV HEMATOLOGIE A KREVNI TRANSFUZE PRAHA (Czechia), MASARYKUV ONKOLOGICKY USTAV (Czechia), REGION SYDDANMARK (Denmark), TARTU ULIKOOL (Estonia), IDA-TALLINNA KESKHAIGLA AS (Estonia), SIHTASUTUS POHJA-EESTI REGIONAALHAIGLA (Estonia), SIHTASUTUS TARTU ULIKOOLI KLIINIKUM (Estonia), HUS-YHTYMA (Finland), INSTITUT NATIONAL DU CANCER GIP (France), BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE (Germany), 1ST YGEIONOMIKI PERIFEREIA DYPE ATTIKIS (Greece), Orszagos Onkologiai Intezet (Hungary), LANDSPITALI UNIVERSITY HOSPITAL (Iceland), HEALTH SERVICE EXECUTIVE (Ireland), ALLEANZA CONTRO IL CANCRO (Italy), ISTITUTO SUPERIORE DI SANITA (Italy), LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS (Latvia), LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS (Lithuania), LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (Lithuania), INSTITUT NATIONAL DU CANCER (Luxembourg), MINISTERU GHAS-SAHHA U L-ANZJANITA ATTIVA (Malta), ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (Netherlands), STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands), ACADEMISCH ZIEKENHUIS LEIDEN (Netherlands), OSLO UNIVERSITETSSYKEHUS HF (Norway), NARODOWY INSTYTUT ONKOLOGII (Poland), MINISTERIO DA SAUDE (Portugal), ONKOLOSKI INSTITUT LJUBLJANA (Slovenia), INSTITUT CATALA D'ONCOLOGIA (Spain), FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (Spain), FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE (Spain), INSTITUTO DE SALUD CARLOS III (Spain), DEPARTAMENTO DE SANIDAD - GOBIERNO DE ARAGON (Spain), SERVIZO GALEGO DE SAUDE (Spain), SERVICIO MADRILENO DE SALUD (Spain), FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON (Spain), SOCIALSTYRELSEN (Sweden), NATIONAL CANCER INSTITUTE STATE NON-PROFIT ENTERPRISE (Ukraine), INSTITUTIA MEDICO-SANITARA PUBLICA INSTITUTUL ONCOLOGIC (Moldova), UNIVERSITATEA DE MEDICINA SI FARMACIE CAROL DAVILA DIN BUCURESTI (Romania).

Funding: The JA PCM project is co-funded by the European Union’s EU4Health programme, managed by the European Health and Digital Executive Agency (HaDEA), under grant agreement No. 101233450.